title: GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts.
abstract: Valerian extracts have been used for centuries to alleviate restlessness and anxiety albeit with unknown mechanism of action in vivo. We now describe a specific binding site on GABA(A) receptors with nM affinity for valerenic acid and valerenol, common constituents of valerian. Both agents enhanced the response to GABA at multiple types of recombinant GABA(A) receptors. A point mutation in the beta2 or beta3 subunit (N265M) of recombinant receptors strongly reduced the drug response. In vivo, valerenic acid and valerenol exerted anxiolytic activity with high potencies in the elevated plus maze and the light/dark choice test in wild type mice. In beta3 (N265M) point-mutated mice the anxiolytic activity of valerenic acid was absent. Thus, neurons expressing beta3 containing GABA(A) receptors are a major cellular substrate for the anxiolytic action of valerian extracts.
authors.affiliation: Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
authors.forename: Dietmar
authors.initials: D
authors.lastname: Benke
authors.forename: Andrea
authors.initials: A
authors.lastname: Barberis
authors.forename: Sascha
authors.initials: S
authors.lastname: Kopp
authors.forename: Karl-Heinz
authors.initials: KH
authors.lastname: Altmann
authors.forename: Monika
authors.initials: M
authors.lastname: Schubiger
authors.forename: Kaspar E
authors.initials: KE
authors.lastname: Vogt
authors.forename: Uwe
authors.initials: U
authors.lastname: Rudolph
authors.forename: Hanns
authors.initials: H
authors.lastname: Möhler
mesh_terms: D000495:Allosteric Site / Q000187:drug effects; D000704:Analysis of Variance; D000818:Animals; D014151:Anti-Anxiety Agents / Q000737:chemistry / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects; D002461:Cell Line, Transformed; D002755:Choice Behavior / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007192:Indenes / Q000737:chemistry / Q000494:pharmacology*; D018782:Maze Learning / Q000187:drug effects; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008817:Mice, Mutant Strains; D016297:Mutagenesis, Site-Directed / Q000379:methods; D009154:Mutation; D018408:Patch-Clamp Techniques; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D021122:Protein Subunits / Q000235:genetics / Q000378:metabolism; D051381:Rats; D011963:Receptors, GABA-A / Q000187:drug effects* / Q000235:genetics; D012717:Sesquiterpenes / Q000737:chemistry / Q000494:pharmacology*; D014316:Tritium / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
chemical_list: D014151:Anti-Anxiety Agents; D007192:Indenes; D010936:Plant Extracts; D021122:Protein Subunits; D011963:Receptors, GABA-A; D012717:Sesquiterpenes; D014316:Tritium; C037133:valerenic acid; D005680:gamma-Aminobutyric Acid